441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Market cap: $116.8M (2/09/2026)
Price: $1.64
Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)
Shareholder votes
Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results
Ovid's OV329 Shows Strong Inhibitory Activity & Best-in-Category Safety
Other Events
Reports Business Updates and Second Quarter 2025 Financial Results
Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
Q2
Q1
FY 2024
Q3
FY 2023
Effectiveness Notice
Prospectus filed pursuant to Rule 424(b)(3)
Registration Statement for Securities to be Offered to Employees
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities Offered under a Shelf Registration
Definitive Proxy Statement
PRE 14A
Additional Proxy Materials
Amended Schedule 13G - Ownership Report
Schedule 13G - Ownership Report
Statement of Changes in Beneficial Ownership
PREM14A
Correspondence
Submission Upload
S-8 POS